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ABSTRACT   
 
Background: Infants with exomphalos major have a high mortality and morbidity. Our 
aims were to identify predictors of survival regardless of the size of the exomphalos and 
determine whether infants with exomphalos minor also suffered morbidity.  
Methods: Patients were classified as having exomphalos major or minor based on 
whether the liver was in the exomphalos sac and the size of the abdominal wall defect. 
The respiratory, gastrointestinal and surgical outcomes of 50 infants with exomphalos, 27 
with exomphalos major, were assessed. Receiver operator characteristic curves (ROC) 
were constructed to identify factors predictive of survival.  
Results: No infant with exomphalos minor died; there were seven deaths in the 
exomphalos major group (p<0.001).  Infants with exomphalos minor who had 
chromosomal abnormalities (six had a genetic diagnosis of Beckwith Weidman syndrome) 
developed severe respiratory distress or chronic respiratory morbidity. Nasogastric 
feeding at discharge was required in 37% with exomphalos major and 17% with 
exomphalos minor. A lower gestational age (area under the ROC (AUROC) = 0.814) and 
birth weight (AUROC 0.797) and longer durations of ventilation (AUROC 0.853) and 
supplementary oxygen (AUROC 0.810) were predictive of mortality.                                                                                                                 
Conclusions:  Infants with exomphalos regardless of size can suffer chronic morbidity.  
Mortality is commonest in those with exomphalos major born at lower gestational ages 
and birth weights.    
 
Key words: death, exomphalos, supplementary oxygen, surgical outcomes, ventilation  
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INTRODUCTION 
 
Exomphalos is a relatively common congenital abnormality, in one study an incidence of 
approximately 1 in 4000 to 7000 live births was reported (1).  A study from the United 
States estimated a prevalence of 1.86 (95% confidence intervals [CI] 1.73–1.99) per 
10,000 live births (2).  Data from six regional congenital anomaly registers in England and 
Wales between 2005 and 2011 demonstrated that the overall birth prevalence of 
exomphalos was 3.8 per 10.000 births; 1.4 per 10,000 isolated cases, 1.2 per 10,000 
cases with multiple anomalies and 1.2 per 10,000 cases with chromosomal anomalies (3). 
The one-year survival of live born babies with an isolated exomphalos was 92% 
compared with 81% in cases with multiple anomalies and 27% in cases with 
chromosomal abnormalities (p<0.001) (3). A previous study from our institution, however, 
demonstrated that less than 10% of the 445 antenatally diagnosed cases reached 
operative repair (4).   
 
Fetal exomphalos diameter/abdominal circumference ratio (OD/AC) ≥0.26 has been 
reported to be associated with increased respiratory, gastrointestinal and surgical 
morbidities (5). In another study, survival and length of stay differed between live born 
non-isolated and isolated exomphalos diagnosed by a prenatal ultrasound (6). The 
outcomes of infants with exomphalos minor, however, have rarely been reported.  Our 
aims were to identify predictors of survival regardless of the size of the exomphalos and 
determine whether infants with exomphalos minor also suffered morbidity.  
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MATERIAL AND METHODS 
 
A review was conducted of the outcomes of all infants with an antenatal diagnosis of 
exomphalos live born between 2004 and 2015 at King’s College Hospital (KCH) NHS 
Foundation Trust.  The infants were identified from a neonatal database, the neonatal unit 
admission book and a surgical database.  Exomphalos major was defined as a defect 
which had more than 50% of the liver in the exomphalos sac and an abdominal wall 
defect greater than five centimetres in diameter.  Infants with smaller defects were 
diagnosed as having exomphalos minor.  None of the infants had cardiac defects 
reflecting that fetuses were more likely to be terminated if they had exomphalos and other 
anomalies including cardiac defects.  In addition, fetuses with major cardiac anomalies 
without other anomalies were preferentially delivered at the regional cardiac centre. 
 
Data retrieved from the medical records included birth weight, gestational age at birth, 
gender and the results of antenatal genetic tests. The duration of mechanical ventilation, 
mode of ventilation including high frequency oscillatory ventilation (HFOV), duration of 
supplemental oxygen, need for inhaled nitric oxide (iNO) or postnatal corticosteroids and 
mortality were also recorded.  Infants with bronchopulmonary dysplasia were those 
diagnosed as having supplementary oxygen dependence beyond 28 days after birth. 
Postnatal corticosteroids were considered for infants who remained ventilator dependent 
with high peak inspiratory pressures and inspired oxygen concentrations after two weeks 
of age. Infants were diagnosed with bronchopulmonary dysplasia if they were oxygen 
dependent beyond 28days after birth. Details of gastrointestinal outcomes including the 
time to commence and reach full enteral feeds were documented, as were the length of 
hospital stay and time to first operative intervention.  Infants underwent primary closure, 
staged closure or delayed closure according to the size of the defect and the infant’s 
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respiratory status, that is, a more conservative approach was undertaken for infants 
requiring high levels of respiratory support.   
 
Statistical analysis 
The data were tested for normality using the Kolmogorov-Smirnov test and found not to 
be normally distributed.  Differences, therefore, were assessed for statistical significance 
using the Mann-Whitney U test or Chi-square test as appropriate.  Receiver operating 
characteristic curves (ROC) were constructed and the area under the curve (AUROC) 
calculated to compare the predictive value of factors which differed on univariate analysis 
at the p < 0.1 level. Sensitivities and specificities were calculated for factors found to be 
most predictive. Analysis was performed using SPSS version 22.0 (SPSS, Inc., Chicago, 
IL). 
 
RESULTS 
 
Fifty infants with exomphalos were live born during the study period, 27 had exomphalos 
major. There were no significant differences in birthweight (p= 0.073) and gestational age 
(p=0.129) between those with major or minor abnormalities (Table1). None of the infants 
in either group had cardiac anomalies.  Six infants in the exomphalos minor group had the 
genetic diagnosis of Beckwith Weidman syndrome and one infant in the exomphalos 
major group had a minor genetic abnormality with duplication in the short arm of 
chromosome eight. The time to first surgical intervention occurred later in infants with 
exomphalos major (four versus two days, p=0.002). Infants with exomphalos major had 
significantly worse adverse respiratory outcomes with longer median durations of 
mechanical ventilation (p<0.001) and supplemental oxygen (p<0.001) and a greater need 
for high frequency oscillatory ventilation (HFOV) (p=0.008) (Table 1). Infants with 
exomphalos major compared to minor commenced enteral feeds (p=0.004) and achieved 
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full enteral feeds (p<0.001) at a greater postnatal age (Table 1). In both groups, however, 
a proportion of infants required nasogastric feeding at discharge, 37% in the exomphalos 
major and 17% in the exomphalos minor groups. The length of hospital stay was longer in 
infants with exomphalos major (p<0.001) (Table 1). Infants with exomphalos minor who 
had chromosomal abnormalities developed severe respiratory distress or chronic 
respiratory morbidity.  No infant with exomphalos minor who did not have chromosomal 
abnormalities developed severe respiratory distress (as defined by the need for HFOV or 
iNO) or chronic respiratory morbidity (defined as development of BPD or need for 
postnatal corticosteroids) (Table 1).   
 
There were seven deaths in the exomphalos major infants and none in those with 
exomphalos minor (p<0.001).  Infants who did not survive were born at an earlier 
gestational age (p=0.006) and of smaller birth weight (p=0.01) and needed longer 
durations of mechanical ventilation (p<0.001) and supplementary oxygen (p<0.001) 
(Table 2). A greater proportion of the non-survivors required nitric oxide (p=0.001), HFOV 
(p<0.001) and postnatal steroids (p=0.048) (Table 2). 
 
In the overall study group, a gestational age > 35 weeks had an AUROC of 0.814 and a 
sensitivity of 83% and 72%, a birth weight > 2497gm had an AUROC of 0.797 and a 
sensitivity of 82% and a specificity of 72% in prediction of survival. Mechanical ventilation 
>15 days had an AUROC of 0.853 with a sensitivity of 85% and a specificity of 80% and a 
duration of supplemental oxygen > 40 days had an AUROC of 0.810 with a sensitivity of 
72% and a specificity of 85% in prediction of mortality. 
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DISCUSSION 
 
We have demonstrated that infants with exomphalos born at lower gestational ages and 
birth weights are at increased risk of mortality. The overall mortality of live born infants 
with exomphalos in our series was 14%, similar to that reported previously (7).  
Importantly, we have also demonstrated that infants with exomphalos minor can suffer 
chronic morbidity as evidenced by the requirement for nasogastric tube feeding at 
discharge.   
 
Prolonged requirement for mechanical ventilation and supplementary oxygen were also 
sensitive and specific predictors of survival.  This likely reflects infants with exomphalos 
are at increased risk of pulmonary hypoplasia due to reduced fetal breathing because of 
poor diaphragmatic function in utero.  Indeed, infants with anterior wall defects (AWD) 
have been shown to have impaired postnatal lung function (8). Infants with AWD studied 
at median age of five months had significantly lower functional residual capacity (FRC) 
than healthy age-matched controls (8). Furthermore, children who had had giant 
exomphalos, when studied at median age of 19.7 months (1-58), had reduced lung 
volume, increased airway hyper- responsiveness and reduced respiratory system specific 
compliance (9).   
  
We report a higher incidence of genetic abnormalities in infants with exomphalos minor 
compared to exomphalos major. This is likely explained by our inclusion of only live born 
infants and fetuses of pregnancies which were terminated or resulted in intrauterine 
deaths would be likely to have had multiple congenital abnormalities and/or severe 
chromosomal abnormalities.  Indeed, a previous study from our institution reported that 
less than 10% of all cases of antenatally diagnosed exomphalos reach an operative stage 
(4).  In 56% of the cases (n=250) there was an abnormal karyotype and from that group 
there were only two live births (4).  In an observational study of 53 patients with 
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gastroschisis and 43 with exomphalos there were no significant differences in outcomes 
between those who were and were not diagnosed antenatally (10).  The rate of antenatal 
detection, however, was low (overall 44%) and there was a low rate of chromosomal 
abnormalities.  It has been suggested that despite advances in ultrasound technology, its 
ability to predict an abnormal karyotype in exomphalos fetuses has not improved (11).  In 
our series of live born infants, only one infant with exomphalos major had a chromosomal 
abnormality and this was of a minor nature, which likely reflects those with major 
chromosomal anomalies were detected antenatally and the parents opted for a 
termination of pregnancy or the infants were stillborn.    
 
Infants with exomphalos major suffered significantly worse respiratory outcomes 
compared to those with exomphalos minor as evidenced by the longer duration of 
mechanical ventilation and supplemental oxygen and the requirement for high frequency 
oscillatory ventilation and/or nitric oxide therapy.  Exomphalos minor infants with 
chromosomal abnormalities, however, suffered severe respiratory distress or chronic 
respiratory morbidity.  Infants with giant exomphalos complicated by pulmonary 
hypertension have been reported to have increased respiratory support requirements with 
a longer duration of mechanical ventilation, requirement for tracheotomy and dependence 
on home oxygen therapy following hospital discharge compared to survivors with no 
associated pulmonary hypertension (12). In a series of 54 infants with giant exomphalos, 
37% had pulmonary hypertension (12). A proportion of infants in our series, more with 
exomphalos major, required iNO and thus likely had pulmonary hypertension.   
We have also demonstrated that infants with exomphalos suffer chronic gastrointestinal 
problems.  The time taken to start and achieve full enteral feeds differed significantly 
between the two groups, yet, there were no significant differences in birth weight or 
gestational age between the two groups and none had a cardiac defect.  The differences 
in the time to start and achieve full enteral feeds likely reflects the more severe respiratory 
abnormalities experienced by the exomphalos major group.  Importantly, 37% of the 
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major group and 17% of the minor group required nasogastric feeding after discharge, 
parents need to be informed this is a possible outcome.  In this study infants had primary 
closure or a silo fashioned.  A recent study of infants with giant exomphalos were treated 
by negative pressure wound therapy, full feeds were achieved by a postnatal age of 19 
days and full closure of the abdominal wall defect by two months of age (13).  Whether 
such an approach would improve better outcomes than current strategies requires testing 
in a randomized trial.   
 
In conclusion, we have demonstrated that infants with exomphalos born at an earlier 
gestation and of lower birth weight are more likely to die.  In addition, a requirement for 
prolonged ventilation and supplementary oxygen also predicted mortality, likely reflecting 
the infants may have had pulmonary hypoplasia.  Infants with exomphalos minor did 
suffer morbidity, these data should be helpful to inform counseling of parents of affected 
infants.    
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Table 1: Demographics and respiratory and gastrointestinal outcomes according to major or minor status 
Data are reported as median (IQR) or n (%) 
 
 
 
 
 
 
 
 
 
 
 
 
 Exomphalos major  Exomphalos minor  P value(1) Exomphalos minor 
without chromosomal 
abnormalities  
P value(2) 
n 27 23  17  
Birth weight (gm) 2810(2272,3166) 3315 (2587-3517) 0.073 3288 (2344, 4276) 0.072 
Gestational age (wks) 38 (36,38) 38 (35.5,38) 0.129 38 (34, 41) 0.072 
Genetic abnormality  1 (3.7%) 7 (30.4%) 0.010   
Gender (male) 12 (44.4%) 8 (34.8%) 0.487 (37.5%) 0.582 
Duration of mechanical 
ventilation (days) 
13.5 (4,32) 2 (1,3) 0.001 1.5 (1, 10) <0.001 
Duration of Oxygen 
therapy (days) 
23 (5,52) 1(1,3) < 0.001 1 (0, 17) <0.001 
Intubation at birth 8 (29.6%) 3 (13%) 0.143 0 (0%) 0.014 
HFOV 8 (29.6%) 0 (0%) 0.008 0 (0%) 0.012 
Nitric oxide 4 (14.8%) 1(4.3%) 0.219 0 (0%) 0.099 
BPD at 28 days 9 (33.3%) 2 (8.7%) 0.036 0 (0%) 0.008 
Postnatal steroids 2 (7.4%) 1 (4.3%) 0.650 0 (0%) 0.256 
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(1) Comparison of all exomphalos minor infants to exomphalos major infants 
(2) Comparison of exomphalos minor infants without chromosomal abnormalities to exomphalos major infants. 
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Table 2:  Demographics and outcomes according to survival status  
 
Data reported as median (range) or n (%) 
 
 Survived  Not survived  P value  
n 43 7  
Gestational age (weeks) 38 (37,39) 33 (33,36) 0.006 
Birth weight (gm) 3090 (2628,3463) 1926 (1735,2801) 0.01 
Gender (male) 17 (39.5%) 3 (42.9%) 0.590 
Duration of mechanical ventilation (days) 4 (1,13) 54 (30,96) 0.002 
Duration of supplementary oxygen (days) 3 (1,24) 54 (30,97) 0.004 
HFOV 2 (4.7) 6 (85.7) <0.001 
Inhaled nitric oxide  1 (2.3) 4 (57.1) 0.001 
BPD 7 (16.3) 4 (57.1) 0.034 
Use of Postnatal steroids  1 (2.3) 2 (28.6) 0.048 
 
 
 
